Stay updated on Daratumumab & DLI for Relapsed AML Clinical Trial
Sign up to get notified when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.

Latest updates to the Daratumumab & DLI for Relapsed AML Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedDifference0.8%
- Check21 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.7%
- Check28 days agoChange DetectedDifference0.9%
- Check35 days agoChange DetectedThe webpage has undergone significant updates, including the removal of detailed descriptions of a clinical trial involving daratumumab and donor lymphocyte infusions for treating relapsed acute myeloid leukemia, while adding a new registry identifier and a revision number.SummaryDifference37%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.6%
- Check49 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.6%
Stay in the know with updates to Daratumumab & DLI for Relapsed AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab & DLI for Relapsed AML Clinical Trial page.